Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

详细信息    查看全文

• 作者：Carlo Marani ; Marino Clavio ; Raffaella Grasso ; Nicoletta Colombo ; Fabio Guolo ; Annalisa Kunkl ; Filippo Ballerini ; Livia Giannoni ; Chiara Ghiggi ; Giuseppina Fugazza ; Jean-Louis Ravetti ; Marco Gobbi ; Maurizio Miglino
• 关键词：Acute myeloid leukemia ; Minimal residual disease ; Flow-cytometry ; Wilms&rsquo ; tumor gene ; Prognosis ; Early response assessment
• 刊名：Leukemia Research
• 出版年：December, 2013
• 年：2013
• 卷：37
• 期：12
• 页码：1606-1611
• 全文大小：791 K

文摘

Fifty uniformly treated adult AML patients were analyzed with respect to pre-treatment and post-induction risk factors. Forty-two patients achieving complete hematological remission were assessed for minimal residual disease (MRD) by WT1 gene expression; 34 by flow-cytometry (flow-MRD). Patients who were flow-MRD negative had a better 3-year disease-free (DFS; 79.5% vs. 27.3%; p = .032) compared with patients who were still positive after induction. Interestingly, DFS of flow-MRD positive patients was not related to the amount of flow-detected clone population (鈮?or <1%, p = .41) but to WT1 reduction (螖WT1, 3-year DFS; 46.2% vs. 0% if 螖WT1 was 鈮?or < of 1.5 log, p = .001). In AML, combining MRD results provided by WT1 quantification and flow-cytometry improves the reliability of MRD-based prognostic stratification. Similar analyses by further larger studies should be advocated.